skip to primary navigationskip to content
 

Owlstone Medicals ReCIVA technology Invention of the Year in Top 50 Digital Health Awards

last modified Jan 06, 2017 03:38 PM
Early diagnosis and health care savings winning combination
Owlstone Medicals ReCIVA technology Invention of the Year in Top 50 Digital Health Awards

Owlstone Medical’s Co-Founder and CEO, Billy Boyle, demonstrating the ReCIVA device.

ReCIVA, or Respiration Collector for In Vitro Analysis for short, meets the needs of a growing field of breath research but reliably and reproducibly capturing breath samples for analysis. In doing so, ReCIVA allows researchers to focus their efforts on analysing the captured samples and detect targeted biomarkers of disease in breath (and other bodily fluids). It can diagnose cancer and other diseases earlier than existing tests, allowing for more effective treatment and ultimately, improved survival rates and reduced treatment costs.

Billy Boyle, co-founder and CEO at Owlstone Medical, said: “We are delighted that ReCIVA has been named Invention in the 2017 Top 50 Digital Health Awards. Our vision is to save 100,000 lives and $1.5B in health care costs by 2020 with a breath sampling and analysis technology that can diagnose cancer and other diseases earlier than existing tests. This allows for more effective treatment and ultimately, better patient survival rates and reduced treatment costs.”

About the Awards

Each year fifty of the leading entrepreneurs, investors, technologists, reporters, and providers dedicated to bringing technological advancements to healthcare are recognized at the Top 50 in Digital Health Dinner hosted by Rock Health, Fenwick & West, Goldman Sachs, and Square 1 Bank.  

Within the Top 50, a number of individuals and organizations are awarded through nominations from the digital health community for making exceptional progress in driving resources, attention, and innovation toward a massively better healthcare system. From writing healthcare policy to steering corporate acquisitions to moving technology from the bench to the bedside, the Awards honor the people and organizations making digital health thrive.

About Owlstone Medical

Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in health care costs by 2020.

The company’s microchip FAIMS (Field Asymmetric Ion Mobility Spectrometer) sensor is a platform technology that can be programmed in software to detect targeted biomarkers of disease in breath (and other bodily fluids).  FAIMS can be used in clinical diagnostics and precision medicine with application in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and where more lives can be saved.

Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by therapeutic response. The company also sells R&D tools and services to academic, clinical and pharma partners who want to develop breath based diagnostics for their own applications. 

Founded in 2004 as a spin-out from the Engineering Department at the University of Cambridge University, Owlstone Inc is a profitable business selling it’s proven FAIMS technology to military and industrial customers globally. Owlstone Medical was spun out from Owlstone Inc in 2016 to develop and commercialise FAIMS in diagnostic applications.

Owlstone Medical is headquartered in Cambridge, UK, with offices in London, UK. 

 

RSS Feed Latest news

Sparrho Spreads its Wings

Jul 17, 2017

Sparrho raises $3 million to democratize access to science research

Silver Medal Awarded to Breath Biopsy Pioneer Billy Boyle

Jul 04, 2017

Owlstone Medical CEO Billy Boyle wins Royal Academy of Engineering’s Silver Medal

ideaSpace Alumni close three funding deals in a week

Jun 26, 2017

£4.3m raised in an exceptional 7 days for SyndicateRoom

Life sciences equity crowdfunding platform, Capital Cell shortlisted for international award

Jun 23, 2017

Shortlisted for the Best International Growth Business award at the UK Business Angels Association Investment Awards 2017

Addenbrooke's takes over the GeneAdviser ordering platform for genetic testing

Jun 21, 2017

GeneAdviser's platform to live on as in-house NHS tool

View all news